The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?

Abstract

We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and appraisal being mixed which results in poorly effective policy measures.

Keywords

• biosimilar
• reference biological
• competitive market
• Belgium